Literature DB >> 22216496

The cardiovascular effects of bromocriptine in Parkinsonism.

J K Greenacre1, P F Teychenne, A Petrie, D B Calne, P N Leigh, J L Reid.   

Abstract

The cardiovascular effects of bromocriptine, a dopamine receptor agonist, were investigated in twenty-eight Parkinsonian patients. Bromocriptine caused a significant impairment of postural compensation with a fall in systolic pressure and an absence of the rise in diastolic pressure after standing for 1 min when patients taking active drug were compared to the same patients on placebo. The hypotensive effect persisted for at least 6 weeks of treatment. There was also a significant reduction in supine heart rate. One patient had marked falls in supine and erect blood pressure after a single oral dose of bromocriptine (2.5 mg) and a further patient developed paroxysmal atrial tachyarrhythmias. Both blood pressure and heart rate changes reversed spontaneously after stopping bromocriptine. It is proposed that dopaminergic mechanisms either in the central nervous system or the periphery contribute to cardiovascular regulation in man.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 22216496      PMCID: PMC1428903          DOI: 10.1111/j.1365-2125.1976.tb04877.x

Source DB:  PubMed          Journal:  Br J Clin Pharmacol        ISSN: 0306-5251            Impact factor:   4.335


  14 in total

Review 1.  Cardiovascular and renal actions of dopamine: potential clinical applications.

Authors:  L I Goldberg
Journal:  Pharmacol Rev       Date:  1972-03       Impact factor: 25.468

Review 2.  Presynaptic regulation of catecholamine release.

Authors:  S Z Langer
Journal:  Biochem Pharmacol       Date:  1974-07-01       Impact factor: 5.858

3.  Evidence for a centrally mediated hypotensive effect of L-dopa in the rat.

Authors:  M Henning; A Rubenson
Journal:  J Pharm Pharmacol       Date:  1970-03       Impact factor: 3.765

4.  Bromocriptine in Parkinsonism.

Authors:  D B Calne; P F Teychenne; L E Claveria; R Eastman; J K Greenacre; A Petrie
Journal:  Br Med J       Date:  1974-11-23

5.  Orthostatic hypotension in Parkinson's disease.

Authors:  M Gross; R Bannister; R Godwin-Austen
Journal:  Lancet       Date:  1972-01-22       Impact factor: 79.321

6.  The action of L(-)-dopa on baroreflexes in Parkinsonism.

Authors:  J L Reid; D B Calne; C F George; S D Vakil
Journal:  Clin Sci       Date:  1972-12       Impact factor: 6.124

7.  Dopamine is an important neurotransmitter in the autonomic nervous system.

Authors:  M O Thorner
Journal:  Lancet       Date:  1975-03-22       Impact factor: 79.321

8.  Bromocriptine treatment of acromegaly.

Authors:  M O Thorner; A Chait; M Aitken; G Benker; S R Bloom; C H Mortimer; P Sanders; A S Mason; G M Besser
Journal:  Br Med J       Date:  1975-02-08

9.  Assessment of autonomic function in patients with a Parkinsonian syndrome.

Authors:  M J Aminoff; C S Wilcox
Journal:  Br Med J       Date:  1971-10-09

10.  Long-term treatment of galactorrhoea and hypogonadism with bromocriptine.

Authors:  M O Thorner; A S McNeilly; C Hagan; G M Besser
Journal:  Br Med J       Date:  1974-05-25
View more
  5 in total

1.  Hemodynamic alterations produced by N,N-Di-n-propyldopamine in anesthetized dogs.

Authors:  R A Hahn; B R MacDonald
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1982-10       Impact factor: 3.000

Review 2.  Bromocriptine in the treatment of parkinsonism.

Authors:  J D Parkes
Journal:  Drugs       Date:  1979-05       Impact factor: 9.546

3.  Bromocriptine in the treatment of hypertension.

Authors:  R J Walden; J Hernandez; P Bhattacharjee; B Graham; B N Prichard
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

4.  Bromocriptine reduces plasma noradrenaline and 3,4-dihydroxyphenylacetic acid in normal and hypotensive subjects.

Authors:  G Mercuro; Z L Rossetti; L Tocco; C A Rivano; A Cherchi; G L Gessa
Journal:  Eur J Clin Pharmacol       Date:  1985       Impact factor: 2.953

5.  The effect of bromocriptine on plasma catecholamine concentrations in normal volunteers.

Authors:  L Steardo; E Di Stasio; S Bonuso; M Maj
Journal:  Eur J Clin Pharmacol       Date:  1986       Impact factor: 2.953

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.